Immune-Related Adverse Events-A Novel Prediction of Nivolumab Efficacy?-Reply

Affiliations

Comment

Koji Haratani et al. JAMA Oncol. 2018.

. 2018 Jul 1;4(7):1017-1018.

doi: 10.1001/jamaoncol.2018.0751.

¹ Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.

No abstract available

Comment on

Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer.
Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, Kaneda H, Hasegawa Y, Tanaka K, Takeda M, Nakagawa K. Haratani K, et al. JAMA Oncol. 2018 Mar 1;4(3):374-378. doi: 10.1001/jamaoncol.2017.2925. JAMA Oncol. 2018. PMID: 28975219 Free PMC article.
Immune-Related Adverse Events-A Novel Prediction of Nivolumab Efficacy?
Cheng Y, Wu Y, Wu L. Cheng Y, et al. JAMA Oncol. 2018 Jul 1;4(7):1017. doi: 10.1001/jamaoncol.2018.0745. JAMA Oncol. 2018. PMID: 29852042 No abstract available.